Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$91.4 million.

  • Ultragenyx Pharmaceutical's Cash from Operations fell 3646.24% to -$91.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.7 million, marking a year-over-year decrease of 647.05%. This contributed to the annual value of -$414.2 million for FY2024, which is 1276.69% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Cash from Operations stood at -$91.4 million, which was down 3646.24% from -$108.3 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Cash from Operations registered a high of -$54.3 million during Q4 2021, and its lowest value of -$190.7 million during Q1 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Cash from Operations value was -$91.4 million (recorded in 2025), while the average stood at -$103.9 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Cash from Operations crashed by 17482.0% in 2021, and later soared by 4316.39% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Cash from Operations stood at -$54.3 million in 2021, then tumbled by 66.24% to -$90.3 million in 2022, then rose by 7.13% to -$83.9 million in 2023, then grew by 5.25% to -$79.5 million in 2024, then fell by 14.99% to -$91.4 million in 2025.
  • Its last three reported values are -$91.4 million in Q3 2025, -$108.3 million for Q2 2025, and -$166.5 million during Q1 2025.